Sunshine Biopharma Inc.

1.25
0.03 (2.46%)
At close: Apr 17, 2025, 3:59 PM
1.26
1.20%
After-hours: Apr 17, 2025, 07:26 PM EDT

Company Description

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs.

The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound.

It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements.

The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4.

Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.

Sunshine Biopharma Inc.
Sunshine Biopharma Inc. logo
Country CA
IPO Date Feb 15, 2022
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 52
CEO Dr. Steve N. Slilaty Ph.D.

Contact Details

Address:
6500 Trans-Canada Highway
Pointe-Claire, QC
CA
Website https://www.sunshinebiopharma.com

Stock Details

Ticker Symbol SBFM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001402328
CUSIP Number 867781304
ISIN Number US8677814035
Employer ID 20-5566275
SIC Code 8731

Key Executives

Name Position
Dr. Steve N. Slilaty Ph.D. Chairman, President & Chief Executive Officer
Camille Sebaaly Chief Financial Officer & Secretary
Dr. Abderrazzak Merzouki Chief Operating Officer & Director
Malek Chamoun Chief Development Officer
Michel Roy Chief Commercial Officer
Robert G. Ferreira President of Sunshine Bio Investments Inc

Latest SEC Filings

Date Type Title
Apr 11, 2025 SCHEDULE 13G Filing
Apr 03, 2025 8-K Current Report
Apr 03, 2025 424B5 Filing
Apr 02, 2025 8-K Current Report
Apr 01, 2025 10-K Annual Report
Mar 31, 2025 NT 10-K Filing
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Jan 21, 2025 3 Filing
Jan 15, 2025 8-K Current Report
Jan 06, 2025 S-3 Filing